Last reviewed · How we verify
Tenoretic 100 (ATENOLOL)
Tenoretic 100 (generic name: ATENOLOL) is a beta-Adrenergic Blocker [EPC] Small molecule drug developed by Twi Pharms. It is currently FDA-approved (first approved 1981) for Angina pectoris, Hypertensive disorder, Myocardial infarction.
Tenoretic 100 is a medication that contains the combination of chlorthalidone and atenolol, a beta-1 adrenergic receptor antagonist. It is used to treat hypertension, as indicated by ClinicalTrials.gov.
At a glance
| Generic name | ATENOLOL |
|---|---|
| Sponsor | Twi Pharms |
| Drug class | beta-Adrenergic Blocker [EPC] |
| Target | Adenosine receptor A3 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Angina pectoris
- Hypertensive disorder
- Myocardial infarction
Common side effects
- Bradycardia
- Hypotension
- Dizziness
- Fatigue
- Vertigo
- Lightheadedness
- Tiredness
- Cold Extremities
- Leg Pain
- Postural Hypotension
- Nausea
- Dyspnea
Drug interactions
- chlorpropamide
- clonidine
- disopyramide
- epinephrine
- felodipine
- glibenclamide
- glipizide
- indomethacin
- piroxicam
- sulindac
- tolazamide
- tolbutamide
Key clinical trials
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF) (PHASE4)
- MEdical Treatment in Idiopathic Ventricular Fibrillation Patients (PHASE4)
- Atenolol for the Prevention of Osteoporosis (APO) (PHASE2)
- Rate Control in Patients With Atrial Fibrillation (NA)
- Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease (PHASE2,PHASE3)
- Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II) (PHASE3)
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenoretic 100 CI brief — competitive landscape report
- Tenoretic 100 updates RSS · CI watch RSS
- Twi Pharms portfolio CI
Frequently asked questions about Tenoretic 100
What is Tenoretic 100?
What is Tenoretic 100 used for?
Who makes Tenoretic 100?
What is the generic name of Tenoretic 100?
What drug class is Tenoretic 100 in?
When was Tenoretic 100 approved?
What development phase is Tenoretic 100 in?
What are the side effects of Tenoretic 100?
What does Tenoretic 100 target?
Related
- Drug class: All beta-Adrenergic Blocker [EPC] drugs
- Target: All drugs targeting Adenosine receptor A3
- Manufacturer: Twi Pharms — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Angina pectoris
- Indication: Drugs for Hypertensive disorder
- Indication: Drugs for Myocardial infarction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing